Manifaxine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Manifaxine
GW-320,659 structure.png
Systematic (IUPAC) name
(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethylmorpholin-2-ol
Clinical data
Legal status ?
Identifiers
CAS number 135306-39-7
ATC code None
PubChem CID 60829
ChemSpider 54816
UNII J8IE53G2IV YesY
Chemical data
Formula C12H15F2NO2 
Mol. mass 243.249 g/mol
 YesY (what is this?)  (verify)

Manifaxine (GW-320,659) is a drug developed by GlaxoSmithKline through structural modification of radafaxine, the active metabolite of bupropion. It acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It was researched for treatment of ADHD and obesity and was shown to be safe, reasonably effective and well tolerated for both applications,[1][2] but no results have been reported following these initial trials and its current status is unclear.

See also[edit]

References[edit]

  1. ^ DeVeaugh-Geiss J, Conners CK, Sarkis EH, Winner PK, Ginsberg LD, Hemphill JM, Laurenza A, Barrows CE, Webster CJ, Stotka CJ, Asgharnejad M. GW320659 for the treatment of attention-deficit/hyperactivity disorder in children. Journal of the American Academy of Child and Adolescent Psychiatry. 2002 Aug;41(8):914-20. PMID 12162627
  2. ^ Spraggs CF, Pillai SG, Dow D, Douglas C, McCarthy L, Manasco PK, Stubbins M, Roses AD. Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects. Pharmacogenetics and Genomics. 2005 Dec;15(12):883-9. PMID 16272960